Steven Wallentine, MD
Hematology & Oncology · Provo, UTNPI 1790736122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.2% — the pattern of someone who eats at a lot of different presentations.
Across 389 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$580
- Novartis$531
- Amgen$467
- AstraZeneca$435
- E.r. Squibb & Sons, L.L.C.$384
- Merck$373
- plus $4K from 54 others
What the payments were for
- Food & beverage$6,91598%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,050 in reported general payments places this provider in the 55th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 57 | $648,594 |
| Lenalidomide | 51 | $488,258 |
| PomalystPomalidomide | 20 | $457,055 |
| ImbruvicaIbrutinib | 25 | $411,867 |
| RevlimidLenalidomide | 22 | $402,770 |
| XtandiEnzalutamide | 25 | $313,342 |
| TagrissoOsimertinib Mesylate | 14 | $235,420 |
| InqoviDecitabine/Cedazuridine | 26 | $233,344 |
| VerzenioAbemaciclib | 14 | $216,769 |
| AlecensaAlectinib Hcl | 11 | $208,003 |
| InlytaAxitinib | 14 | $194,773 |
| VenclextaVenetoclax | 12 | $146,566 |
| OrgovyxRelugolix | 30 | $79,330 |
| Abiraterone Acetate | 55 | $27,688 |
| EliquisApixaban | 26 | $16,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $435 | $884,01371 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $384 | $457,05520 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $40 | $411,86725 claims |
| Bristol Myers SquibbRevlimid | $138 | $402,77022 claims |
| Astellas Pharma US IncXtandi | $301 | $313,34225 claims |
| Lilly USA, LLCVerzenio | $124 | $216,76914 claims |
| PfizerInlyta, Eliquis | $580 | $210,99140 claims |
| Genentech USA, Inc.Alecensa | $207 | $208,00311 claims |
| AbbVieVenclexta | $102 | $146,56612 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $38 | $79,33030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Provo
- Nathan RichProvo$14K
- Marc NuttallProvo$12K
- Brandt EsplinProvo$4K
- Nathan PetersonProvo$3K
- Daniel SimsProvo$2K
- David RirieProvo$1K
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.